BioTech IP Review

Assignee: Codexis, Inc.
Patent Number: 12,371,678 B2
Filed: (typically priority from earlier dates; published grant in 2025)
Issued: July 29, 2025
Inventors: Scott J. Novick, Nikki Dellas, Oscar Alvizo, Ravi David Garcia, Charlene Ching, David Entwistle

---

What This Patent Covers

This patent protects engineered transaminase enzymes — specialized biocatalysts that convert substrates into chiral amine compounds under industrially relevant conditions. The invention includes:

• Engineered transaminase polypeptides with enhanced catalytic properties suitable for industrial use (e.g., stability, activity, selectivity).
• Polynucleotides encoding the engineered transaminases and host cells capable of expressing them.
• Methods of using the engineered enzymes to synthesize chiral amines, which are valuable intermediates in pharmaceutical and chemical synthesis.

Chiral amines are building blocks for many active pharmaceutical ingredients (APIs), advanced intermediates, and specialty chemicals — making efficient biocatalytic processes highly desirable.

---

Why This Patent Is Important

• Core to business model: Codexis’s platform CodeEvolver® is focused on designing high‑performance enzymes that improve manufacturing processes for drugs and chemicals. Patents on optimized transaminases directly protect products and processes that generate revenue through enzyme supply and licensing to pharmaceutical makers.
• Broad industrial relevance: Engineered transaminases are widely used in the synthesis of APIs and fine chemicals, including enantiomerically pure amine intermediates, which are critical for efficacious and cost‑effective drug production.
• Supports partnership revenue: Codexis’s tools and enzymes are incorporated in large pharma manufacturing processes — protecting these enzyme designs helps secure ongoing supply contracts, milestone payments, and potentially royalties.
• Strengthens IP moat: As the company adds patented biocatalysts, it creates barriers to competitors in enzyme engineering and biocatalysis services.

---

U.S. Patent No. 12,371,678 B2, issued July 29, 2025, is among Codexis’s most commercially important patents of 2025. It protects engineered transaminase enzymes and related methods that are widely applicable in pharmaceutical and industrial biocatalysis — a core revenue‑generating area for the company’s enzyme platform.